CSPC Aktie

 

CSPC PHARMA (01093.HK) announced that SYH2083 eye drops, a Class 1 innovative chemical drug developed by the group, has been approved by the National Medical Products Administration to commence clinical trials in China.(ha/a)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chi......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

CSPC PHARMA (01093.HK) announced that the Phase I clinical trial of SYH2092 injection developed by the group for weight management in overweight or obese adult patients has officially commenced at the first research center in China.SYH2092 is an amylin receptor agonist. Through optimized fatty acid modification, it can extend th......

CSPC PHARMA (01093.HK) announced that the SYH2092 injection developed by the group has been approved by the National Medical Products Administration of China to commence clinical trials in China.The product is an amylin receptor agonist. By optimizing agonist activity, the product is expected to improve efficacy while maintainin......

CSPC PHARMA (01093.HK) announced that SYS 6090 (JMT108), a first-in-class PD-1/ IL-15 bispecific fusion protein developed by the group, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastati......

CSPC PHARMA (01093.HK) announced that the Phase III clinical study of SYS 6010 developed by the group recently achieved the preset primary endpoint of progression-free survival after review and assessment by the Independent Data Monitoring Committee. The study evaluated the product as a monotherapy versus platinum-containing che......

CSPC PHARMA (01093.HK) announced that SYS 6057, a Class 1 preventive biological product and recombinant respiratory syncytial virus vaccine developed by the group, has received approval from the US Food and Drug Administration (FDA) to commence clinical trials in the United States. Previously, SYS 6057 had already obtained appro......

G Sachs published a research report stating that driven by licensing fee income of about RMB5.7 billion, CSPC PHARMA (01093.HK)'s 2Q revenue surged 94% YoY, while finished drug sales grew 16% YoY, accelerating from 6% growth in 1Q. Net profit jumped 389% YoY. Excluding the licensing fee income recognized in 2Q, core earnings wer......

UBS published a research report stating that CSPC PHARMA (01093.HK)'s revenue for 1H26 increased 40% YoY, while net profit rose 139%, in line with the earlier profit alert. Growth in licensing fee income and finished drug sales was slightly above guidance. In 2Q26 alone, finished drug sales increased 15.9% YoY and rose 0.2% QoQ,......

Citi said in a report that CSPC PHARMA (01093.HK)'s net profit attributable for 1H26 was RMB6.1 billion, up 139% YoY, at the high end of its profit alert range. Revenue rose 40% YoY to RMB18.6 billion, driven by RMB5.9 billion in licensing income. Excluding licensing income, finished drug sales increased 11% YoY to RMB10.2 billi......

BofAS issued a report saying that CSPC PHARMA (01093.HK)'s total revenue/ net profit attributable for 1H26 rose 40.1%/ 139.2% YoY to RMB18.6 billion/ RMB6.1 billion respectively. In 2Q alone, total revenue increased 93.8% YoY to RMB12.1 billion. Net profit attributable surged 389.3% YoY to RMB5.2 billion.The broker raised its 20......

M Stanley issued a report stating that after CSPC PHARMA (01093.HK)'s 2Q results, it updated its model. EPS estimates for 2026, 2027 and 2028 were raised by 10%, 11% and 10%, respectively, mainly reflecting faster collection progress of business development revenue and observed revenue recognition trends. At the same time, it al......

CSPC PHARMA (01093.HK) shares surged more than 15% this morning. In a research report, CLSA said the unusual share price movement was mainly driven by positive topline results from the Phase III INTerpath-001 clinical trial of personalized mRNA cancer therapy intismeran (combined with Keytruda) for Stage IIB to IV melanoma, join......

CSPC PHARMA (01093.HK) announced its interim results for the period ended June 2026. Revenue rose 40.1% YoY to RMB18.594 billion; net profit reached RMB6.094 billion, up 139.2% YoY; basic EPS was RMB0.5345. Under non-HKFRS, underlying profit amounted to RMB6.164 billion, up 165.8% YoY.The board declared an interim dividend of HK......

CSPC PHARMA (01093.HK) opened 9.38% higher today and once reached HKD10.04. The stock was last reported at HKD9.985, up 14.97%, with trading volume of 136 million shares involving HKD1.342 billion.CSPC PHARMA announced that the Phase Ib/II clinical trial of SYS 6090 Injection developed by the group for the treatment of hepatocel......

CSPC PHARMA (01093.HK) announced that the new drug application for KN026, anetumab developed jointly by subsidiary Jinmant Biotech and ALPHAMAB-B (09966.HK), in combination with the group's self-developed docetaxel for injection HB1801 for first-line treatment of advanced breast cancer, has been accepted by China's National Medi......

CSPC PHARMA (01093.HK) announced the 1H results of its subsidiary INNOVATION (300765.SZ). Revenue amounted to RMB3.24 billion, up 208.7% YoY. Net profit attributable to shareholders reached RMB1.261 billion, compared with a loss of RMB2.75 million in the corresponding period last year, swinging into profit. EPS was RMB0.9056. (d......

CSPC PHARMA (01093.HK) announced that on August 12, it received a USD30 million upfront payment from AstraZeneca under the siRNA drug development collaboration, option and licensing agreement, marking the smooth progress of the cooperation between the two parties. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis artic......

CSPC PHARMA (01093.HK) announced that the Phase I clinical trial of SYS6063, developed by the group for the treatment of relapsed and refractory systemic lupus erythematosus, has officially commenced at the first clinical site in China. SYS6063 is currently the world's first LNP-mRNA transfection-based CD19/BCMA-targeted chimeri......

CSPC PHARMA (01093.HK) announced that SYS6037 injection (monkeypox mRNA vaccine), a Category 1 preventive biological product jointly developed by the group and the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the US Food and Drug Administration (FDA) for clinical trials in the US.The product......